Introduction
Cancer immunotherapy has been revolutionized by PD-L1 checkpoint inhibitors, though most current treatments are monoclonal antibodies requiring intravenous administration. IMMH-010 is a novel small-molecule prodrug designed to overcome these limitations through oral delivery. Upon administration, IMMH-010 is rapidly converted into its active metabolite, YPD-29B. Characterizing the Absorption, Distribution, Metabolism, and Excretion (ADME) profile of this drug candidate is critical for its clinical progression.
Analytical Methodology
A significant challenge in analyzing IMMH-010 and YPD-29B simultaneously is their differing chemical properties; the prodrug ionizes most efficiently in positive mode, whereas the metabolite prefers negative mode. To address this, researchers developed a high-efficiency Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) method utilizing rapid polarity switching.
The method employs a Zorbax SB-C18 column for separation and a stabilized protocol using sodium fluoride (NaF) to prevent prodrug degradation in biological samples. The mass spectrometer is programmed to detect YPD-29B in negative ion mode during the initial phase of the run, followed by an instantaneous switch to positive ion mode for IMMH-010 detection. This unified approach reduces analysis time and sample volume by 50% compared to traditional dual-method strategies.
Pharmacokinetic and Tissue Distribution Results
Pharmacokinetic studies in Sprague-Dawley rats demonstrated that IMMH-010 is a highly effective prodrug, undergoing rapid and extensive conversion to YPD-29B. Both compounds reached peak plasma concentrations ($C_{max}$) within 0.5 to 1 hour. Within the 10–100 mg/kg dose range, the drug exhibited linear kinetics, with internal exposure (AUC) increasing proportionally to the dose.
Tissue distribution analysis revealed significant localization in the lymphatic system. IMMH-010 was primarily found in the adrenal glands, lymph nodes, heart, liver, and spleen. YPD-29B was predominantly observed in the liver, lymph nodes, kidneys, and lungs. This high distribution in lymphatic tissues is particularly advantageous for immunotherapy, as these are primary sites for immune cell trafficking.
Excretion and Mass Balance
The study tracked drug recovery over a 72-hour period, finding that approximately 28.81% of the administered dose was recovered in urine and feces. Fecal excretion was the dominant pathway, with the active metabolite YPD-29B accounting for 20.82% of the total dose and unchanged IMMH-010 accounting for 7.99%. The relatively low total recovery suggests the presence of additional metabolites not captured by the current method, indicating a need for broader metabolic profiling in future studies.
Conclusion
The developed polarity-switching LC-MS/MS method provides a robust and sensitive tool for the simultaneous quantification of IMMH-010 and YPD-29B. The resulting ADME data supports the further development of IMMH-010 as a promising oral PD-L1 inhibitor, with favorable lymphatic targeting and predictable pharmacokinetic behavior.
Clinical Trial Registration: NCT04343859
Summary updated